POINT Biopharma Global Analysis
| PNTDelisted Stock | USD 12.50 0.00 0.00% |
POINT Biopharma Global is overvalued with Real Value of 10.96 and Hype Value of 12.5. The main objective of POINT Biopharma delisted stock analysis is to determine its intrinsic value, which is an estimate of what POINT Biopharma Global is worth, separate from its market price. There are two main types of POINT Biopharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect POINT Biopharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of POINT Biopharma's stock to identify patterns and trends that may indicate its future price movements.
The POINT Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. POINT Biopharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. POINT Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and POINT Biopharma's ongoing operational relationships across important fundamental and technical indicators.
POINT |
POINT Stock Analysis Notes
About 15.0% of the company outstanding shares are owned by corporate insiders. The book value of POINT Biopharma was at this time reported as 4.01. The company had not issued any dividends in recent years. POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. Point Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. To find out more about POINT Biopharma Global contact Joe McCann at 647 812 2417 or learn more at https://www.pointbiopharma.com.POINT Biopharma Global Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. POINT Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding POINT Biopharma Global or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| POINT Biopharma is not yet fully synchronised with the market data | |
| POINT Biopharma has a very high chance of going through financial distress in the upcoming years | |
| About 15.0% of the company outstanding shares are owned by corporate insiders |
POINT Biopharma Global Upcoming and Recent Events
Earnings reports are used by POINT Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to POINT Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
POINT Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 1.33 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate POINT Biopharma's market, we take the total number of its shares issued and multiply it by POINT Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.POINT Profitablity
POINT Biopharma's profitability indicators refer to fundamental financial ratios that showcase POINT Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, POINT Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, POINT Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of POINT Biopharma's profitability requires more research than a typical breakdown of POINT Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of 0.4 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of (10.62) %, which entails that for every $100 of revenue, it lost $10.62. POINT Biopharma Global Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific POINT Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on POINT Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases POINT Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bvf Partners L P over three months ago Sale by Bvf Partners L P of 8974245 shares of POINT Biopharma | ||
Joe McCann over three months ago POINT Biopharma exotic insider transaction detected | ||
Bvf Partners L P over three months ago POINT Biopharma exotic insider transaction detected | ||
Fleshner Neil E over three months ago Bona fide gift to Fleshner Neil E of 250000 shares of POINT Biopharma subject to Section 16 | ||
Martell Bridget A over six months ago Acquisition by Martell Bridget A of 80503 shares of POINT Biopharma subject to Rule 16b-3 | ||
Goodman Jonathan R over six months ago Acquisition by Goodman Jonathan R of 44749 shares of POINT Biopharma subject to Rule 16b-3 | ||
Demers William L over a year ago Acquisition by Demers William L of 131355 shares of POINT Biopharma subject to Rule 16b-3 | ||
Hogue Gerald L over a year ago Exercise or conversion by Hogue Gerald L of 17936 shares of POINT Biopharma subject to Rule 16b-3 |
POINT Biopharma Predictive Daily Indicators
POINT Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of POINT Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About POINT Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how POINT Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling POINT shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as POINT Biopharma. By using and applying POINT Stock analysis, traders can create a robust methodology for identifying POINT entry and exit points for their positions.
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. Point Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding POINT Biopharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |